<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692676</url>
  </required_header>
  <id_info>
    <org_study_id>0205-0537</org_study_id>
    <nct_id>NCT03692676</nct_id>
  </id_info>
  <brief_title>Characteristics of Pts Initiating Spiriva Respimat in Asthma</brief_title>
  <official_title>Characteristics of Patients Initiating Spiriva Respimat in Asthma in the UK: a Cross-sectional Study Based on the Clinical Practice Research Datalink</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a cross-sectional, non-interventional study based on existing data (NISed).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The UK CPRD data will be used to assess the characteristics of asthma patients who were&#xD;
      prescribed ICS/LABA FDC before the index date and who initiated Spiriva Respimat, or received&#xD;
      a higher dose of ICS/LABA FDC, or initiated LTRA, or switched to a new ICS/LABA FDC in the UK&#xD;
      during the study period (September 2014-December 2017) enabling to assess potential&#xD;
      channeling of prescribing to different patient populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Actual">October 11, 2019</completion_date>
  <primary_completion_date type="Actual">October 11, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Cardiac Arrhythmias</measure>
    <time_frame>On the index date or in the year prior to the index date</time_frame>
    <description>The number of participants who had Cardiac arrhythmias on the index date or in the year prior to the index date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Failure</measure>
    <time_frame>On the index date or in the year prior to the index date</time_frame>
    <description>The number of participants who had Cardiac failure on the index date or in the year prior to the index date.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">116133</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Subjects with Asthma</arm_group_label>
    <description>Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spiriva Respimat</intervention_name>
    <description>soft-mist inhaler</description>
    <arm_group_label>Subjects with Asthma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asthmatic patients who were prescribed ICS/LABA FDC before the index date and who initiated&#xD;
        Spiriva Respimat, or received a higher dose of ICS/LABA FDC, or initiated LTRA, or switched&#xD;
        to a new ICS/LABA FDC from the previous ICS/LABA FDC in the UK during the study period&#xD;
        (September, 2014-December 31, 2017)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years and above at the index date&#xD;
&#xD;
          -  At least 12 months of continuous registration prior to the index date in a practice&#xD;
             contributing up to standard (UTS) data to the Clinical Practice Research Database&#xD;
             (CPRD)&#xD;
&#xD;
          -  Had a diagnosis of asthma before the index date&#xD;
&#xD;
          -  Being treated with Inhaled corticosteroids/Long-acting beta agonists (ICS LABA FDC)&#xD;
             before the index date (at least one prescription within 3 months before the index&#xD;
             date)&#xD;
&#xD;
          -  Patients who were new users of Spiriva Respimat, or LTRA, or patients who were&#xD;
             prescribed a higher dose of ICS/LABA FDC, or patients who switched to a new ICS/LABA&#xD;
             FDC from the previous ICS/LABA FDC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were prescribed other Long-acting muscarinic antagonists (LAMA) any time&#xD;
             before or on the index date&#xD;
&#xD;
          -  In the primary analysis, patients who were diagnosed with COPD before or on the index&#xD;
             date will be excluded from the study. In a sensitivity analysis, patients who had both&#xD;
             asthma and COPD diagnoses will be included in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boehringer Ingelheim</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>December 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03692676/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03692676/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study is a cross-sectional assessment of asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma in the UK during the study period (September, 2014-December 31, 2017). (Non-interventional study based on existing data).</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in trial. Subjects meeting the exclusion criteria were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Spiriva Respimat</title>
          <description>The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior Spiriva Respimat use before index date&#xD;
no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date&#xD;
no prior asthma Diagnosis Record (Dx) before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior Up-to-standard (UTS) registration&#xD;
prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)&#xD;
any prior Long-acting muscarinic antagonists (LAMA) use (including index date)</description>
        </group>
        <group group_id="P2">
          <title>Leukotriene Receptor Antagonist (LTRA)</title>
          <description>The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior LTRA use before index date&#xD;
no ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
        </group>
        <group group_id="P3">
          <title>ICS/LABA Fixed Dose Combination (Switchers)</title>
          <description>The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.&#xD;
Patients will be excluded if they fulfil any of the following exclusion criteria:&#xD;
prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date&#xD;
preceding ICS/LABA FDC Rx not within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
        </group>
        <group group_id="P4">
          <title>ICS Dose Increase of ICS/LABA Fixed Dose Combination User</title>
          <description>The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
preceding ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (incl. index date)&#xD;
any prior LAMA use before index date (incl. index date)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10365"/>
                <participants group_id="P2" count="51142"/>
                <participants group_id="P3" count="49479"/>
                <participants group_id="P4" count="5147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="940"/>
                <participants group_id="P2" count="3704"/>
                <participants group_id="P3" count="11135"/>
                <participants group_id="P4" count="1561"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9425"/>
                <participants group_id="P2" count="47438"/>
                <participants group_id="P3" count="38344"/>
                <participants group_id="P4" count="3586"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>exclude patients with prior use</title>
              <participants_list>
                <participants group_id="P1" count="4424"/>
                <participants group_id="P2" count="24726"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients without concurrent ICS/LABA FDC use</title>
              <participants_list>
                <participants group_id="P1" count="2480"/>
                <participants group_id="P2" count="19037"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients without prior recorded asthma diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="881"/>
                <participants group_id="P2" count="563"/>
                <participants group_id="P3" count="6281"/>
                <participants group_id="P4" count="558"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients less than 18 years of age on index date</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="613"/>
                <participants group_id="P3" count="836"/>
                <participants group_id="P4" count="193"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with less than 1 year prior continous UTS enrollment</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="717"/>
                <participants group_id="P3" count="1723"/>
                <participants group_id="P4" count="273"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with prior LAMA use (any time prior to index date)</title>
              <participants_list>
                <participants group_id="P1" count="1208"/>
                <participants group_id="P2" count="759"/>
                <participants group_id="P3" count="7419"/>
                <participants group_id="P4" count="684"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with prior recorded COPD diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="1515"/>
                <participants group_id="P4" count="173"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with multiple FDC prescriptions on index date</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1147"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with prior use of same substances and device</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3700"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients without ICS/LABA FDC prescription within 3 months prior to index date</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14965"/>
                <participants group_id="P4" count="1198"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with different substance(s)/device at preceding prescription</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="223"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="805"/>
                <participants group_id="P3" count="758"/>
                <participants group_id="P4" count="277"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>exclude patients with multiple substance(s)/device at preceding prescription</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the study period (Sep 2014 - Dec 2017).</population>
      <group_list>
        <group group_id="B1">
          <title>Spiriva Respimat</title>
          <description>The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior Spiriva Respimat use before index date&#xD;
no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date&#xD;
no prior asthma Diagnosis Record (Dx) before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior Up-to-standard (UTS) registration&#xD;
prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)&#xD;
any prior Long-acting muscarinic antagonists (LAMA) use (including index date)</description>
        </group>
        <group group_id="B2">
          <title>Leukotriene Receptor Antagonist (LTRA)</title>
          <description>The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior LTRA use before index date&#xD;
no ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
        </group>
        <group group_id="B3">
          <title>ICS/LABA Fixed Dose Combination (Switchers)</title>
          <description>The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.&#xD;
Patients will be excluded if they fulfil any of the following exclusion criteria:&#xD;
prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date&#xD;
preceding ICS/LABA FDC Rx not within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
        </group>
        <group group_id="B4">
          <title>ICS Dose Increase of ICS/LABA Fixed Dose Combination User</title>
          <description>The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
preceding ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (incl. index date)&#xD;
any prior LAMA use before index date (incl. index date)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="940"/>
            <count group_id="B2" value="3704"/>
            <count group_id="B3" value="11135"/>
            <count group_id="B4" value="1561"/>
            <count group_id="B5" value="17340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.22" spread="15.741"/>
                    <measurement group_id="B2" value="49.12" spread="16.299"/>
                    <measurement group_id="B3" value="53.31" spread="16.961"/>
                    <measurement group_id="B4" value="51.91" spread="17.189"/>
                    <measurement group_id="B5" value="52.34" spread="16.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="653"/>
                    <measurement group_id="B2" value="2479"/>
                    <measurement group_id="B3" value="7121"/>
                    <measurement group_id="B4" value="979"/>
                    <measurement group_id="B5" value="11232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="1225"/>
                    <measurement group_id="B3" value="4014"/>
                    <measurement group_id="B4" value="582"/>
                    <measurement group_id="B5" value="6108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="367"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="527"/>
                    <measurement group_id="B2" value="1996"/>
                    <measurement group_id="B3" value="5896"/>
                    <measurement group_id="B4" value="776"/>
                    <measurement group_id="B5" value="9195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                    <measurement group_id="B2" value="1548"/>
                    <measurement group_id="B3" value="4859"/>
                    <measurement group_id="B4" value="720"/>
                    <measurement group_id="B5" value="7493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cardiac Arrhythmias</title>
        <description>The number of participants who had Cardiac arrhythmias on the index date or in the year prior to the index date.</description>
        <time_frame>On the index date or in the year prior to the index date</time_frame>
        <population>Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the studied period (Sep 2014 - Dec 2017).</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva Respimat</title>
            <description>The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior Spiriva Respimat use before index date&#xD;
no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date&#xD;
no prior asthma Diagnosis Record (Dx) before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior Up-to-standard (UTS) registration&#xD;
prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)&#xD;
any prior Long-acting muscarinic antagonists (LAMA) use (including index date)</description>
          </group>
          <group group_id="O2">
            <title>Leukotriene Receptor Antagonist (LTRA)</title>
            <description>The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior LTRA use before index date&#xD;
no ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
          </group>
          <group group_id="O3">
            <title>ICS/LABA Fixed Dose Combination (Switchers)</title>
            <description>The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.&#xD;
Patients will be excluded if they fulfil any of the following exclusion criteria:&#xD;
prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date&#xD;
preceding ICS/LABA FDC Rx not within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
          </group>
          <group group_id="O4">
            <title>ICS Dose Increase of ICS/LABA Fixed Dose Combination User</title>
            <description>The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
preceding ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (incl. index date)&#xD;
any prior LAMA use before index date (incl. index date)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Arrhythmias</title>
          <description>The number of participants who had Cardiac arrhythmias on the index date or in the year prior to the index date.</description>
          <population>Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the studied period (Sep 2014 - Dec 2017).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="940"/>
                <count group_id="O2" value="3704"/>
                <count group_id="O3" value="11135"/>
                <count group_id="O4" value="1561"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Failure</title>
        <description>The number of participants who had Cardiac failure on the index date or in the year prior to the index date.</description>
        <time_frame>On the index date or in the year prior to the index date</time_frame>
        <population>Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the studied period (Sep 2014 - Dec 2017).</population>
        <group_list>
          <group group_id="O1">
            <title>Spiriva Respimat</title>
            <description>The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior Spiriva Respimat use before index date&#xD;
no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date&#xD;
no prior asthma Diagnosis Record (Dx) before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior Up-to-standard (UTS) registration&#xD;
prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)&#xD;
any prior Long-acting muscarinic antagonists (LAMA) use (including index date)</description>
          </group>
          <group group_id="O2">
            <title>Leukotriene Receptor Antagonist (LTRA)</title>
            <description>The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior LTRA use before index date&#xD;
no ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
          </group>
          <group group_id="O3">
            <title>ICS/LABA Fixed Dose Combination (Switchers)</title>
            <description>The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.&#xD;
Patients will be excluded if they fulfil any of the following exclusion criteria:&#xD;
prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date&#xD;
preceding ICS/LABA FDC Rx not within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
          </group>
          <group group_id="O4">
            <title>ICS Dose Increase of ICS/LABA Fixed Dose Combination User</title>
            <description>The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
preceding ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (incl. index date)&#xD;
any prior LAMA use before index date (incl. index date)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Failure</title>
          <description>The number of participants who had Cardiac failure on the index date or in the year prior to the index date.</description>
          <population>Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the studied period (Sep 2014 - Dec 2017).</population>
          <units>Patients with cardiac failures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="940"/>
                <count group_id="O2" value="3704"/>
                <count group_id="O3" value="11135"/>
                <count group_id="O4" value="1561"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA = &lt;5, for compliance with Independent Scientific Advisory Committee (ISAC) requirements, any covariate resulting in counts less than 5 will be reported as &quot;&lt;5&quot; without any further reporting.</measurement>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In this non-interventional study based on existing data, All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.</time_frame>
      <desc>In this non-interventional study based on existing data, All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Spiriva Respimat</title>
          <description>The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior Spiriva Respimat use before index date&#xD;
no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date&#xD;
no prior asthma Diagnosis Record (Dx) before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior Up-to-standard (UTS) registration&#xD;
prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)&#xD;
any prior Long-acting muscarinic antagonists (LAMA) use (including index date)</description>
        </group>
        <group group_id="E2">
          <title>Leukotriene Receptor Antagonist (LTRA)</title>
          <description>The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
prior LTRA use before index date&#xD;
no ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
        </group>
        <group group_id="E3">
          <title>ICS/LABA Fixed Dose Combination (Switchers)</title>
          <description>The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.&#xD;
Patients will be excluded if they fulfil any of the following exclusion criteria:&#xD;
prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date&#xD;
preceding ICS/LABA FDC Rx not within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (including index date)&#xD;
any prior LAMA use before index date (including index date)</description>
        </group>
        <group group_id="E4">
          <title>ICS Dose Increase of ICS/LABA Fixed Dose Combination User</title>
          <description>The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.&#xD;
Patients will be excluded if they fulfill any of the following exclusion criteria:&#xD;
preceding ICS/LABA FDC Rx within 3 months before index date&#xD;
no prior asthma Dx before index date&#xD;
age on index date less than 18 years&#xD;
on index date less than 365 days prior UTS registration&#xD;
prior COPD Dx before index date (incl. index date)&#xD;
any prior LAMA use before index date (incl. index date)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

